CAR-T細胞療法の世界市場の規模は、2024年に46億5,000万ドルと推定され、2025年から2030年にかけてCAGR 22.2%で成長すると予想されます。 急性リンパ芽球性白血病(ALL)や非ホジキンリンパ腫(NHL)などの血液がんの治療における目覚ましい成功により、CAR-T細胞療法の採用が増加し、業界の成長を後押しすることが期待されています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease Indication
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Outlook
2.2.2. Disease indication Outlook
2.2.3. End Use Outlook
2.2.4. Regional Outlook
2.3. Competitive Insights
Chapter 3. CAR T-cell Therapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. CAR T-cell Therapy Market Analysis tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. CAR T-cell Therapy Market: Product Movement Analysis
4.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
4.4. Abecma (idecabtagene vicleucel)
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Breyanzi (lisocabtagene maraleucel)
4.5.1. ket Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Carvykti (ciltacabtagene autoleucel)
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Kymriah (tisagenlecleucel)
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.8. Tecartus (brexucabtagene autoleucel)
4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.9. Yescarta (axicabtagene ciloleucel)
4.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis
5.1. Disease Indication Segment Dashboard
5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
5.3. Global CAR T-cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
5.4. Leukemia
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Lymphoma
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Multiple Myeloma
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. CAR T-cell Therapy Market: End Use Estimates & Trend Analysis
6.1. Product Segment Dashboard
6.2. CAR T-cell Therapy Market: End-use Movement Analysis
6.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Cancer Treatment Centers
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. CAR T-cell Therapy Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous Bioprocessing Market By Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key Country Dynamics
7.4.1.2. Regulatory Framework/ Reimbursement Structure
7.4.1.3. Competitive Scenario
7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework/ Reimbursement Structure
7.4.2.3. Competitive Scenario
7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. Germany
7.5.1.1. Key Country Dynamics
7.5.1.2. Regulatory Framework/ Reimbursement Structure
7.5.1.3. Competitive Scenario
7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework/ Reimbursement Structure
7.5.2.3. Competitive Scenario
7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Regulatory Framework/ Reimbursement Structure
7.6.1.3. Competitive Scenario
7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework/ Reimbursement Structure
7.6.2.3. Competitive Scenario
7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. Rest of World
7.7.1.1. Key Country Dynamics
7.7.1.2. Regulatory Framework/ Reimbursement Structure
7.7.1.3. Competitive Scenario
7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
8.4.1. Bristol-Myers Squibb Company
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Gilead Sciences, Inc.
8.4.3.1. Company Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Johnson & Johnson Services, Inc.
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. bluebird bio, Inc.
8.4.6.1. Company Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Merck & Co., Inc.
8.4.7.1. Company Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Sangamo Therapeutics
8.4.8.1. Company Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Sorrento Therapeutics, Inc.
8.4.9.1. Company Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. GSK plc.
8.4.10.1. Company Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 3 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 4 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 5 North America CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 8 U.S. CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 9 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 10 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 11 Canada CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 12 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 13 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 14 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 15 Europe CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 16 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 17 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 18 Germany CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 19 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 20 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 21 UK CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 22 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 23 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 24 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 25 Asia Pacific CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 26 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 27 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 28 Japan CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 29 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 30 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 31 China CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 32 Rest of World CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 33 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 34 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 35 Rest of World CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 CAR T-cell therapy market: Market outlook
Fig. 10 CAR T-cell therapy competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 CAR T-cell therapy market driver impact
Fig. 16 CAR T-cell therapy market restraint impact
Fig. 17 CAR T-cell therapy market strategic initiatives analysis
Fig. 18 CAR T-cell therapy market: Product movement analysis
Fig. 19 CAR T-cell therapy market: Product outlook and key takeaways
Fig. 20 Abecma (idecabtagene vicleucel) market estimates and forecast, 2018 - 2030
Fig. 21 Breyanzi (lisocabtagene maraleucel) market estimates and forecast, 2018 - 2030
Fig. 22 Carvykti (ciltacabtagene autoleucel) market estimates and forecast, 2018 - 2030
Fig. 23 Kymriah (tisagenlecleucel) market estimates and forecast, 2018 - 2030
Fig. 24 Tecartus (brexucabtagene autoleucel) market estimates and forecast, 2018 - 2030
Fig. 25 Yescarta (axicabtagene ciloleucel) market estimates and forecast, 2018 - 2030
Fig. 26 Other market estimates and forecast, 2018 - 2030
Fig. 27 CAR T-cell therapy market: Disease indication movement analysis
Fig. 28 CAR T-cell therapy market: Disease indication outlook and key takeaways
Fig. 29 Leukemia market estimates and forecasts, 2018 - 2030
Fig. 30 Lymphoma market estimates and forecasts,2018 - 2030
Fig. 31 Multiple Myeloma market estimates and forecasts, 2018 - 2030
Fig. 32 Other market estimates and forecasts, 2018 - 2030
Fig. 33 CAR T-cell therapy market: End use movement analysis
Fig. 34 CAR T-cell therapy market: End use outlook and key takeaways
Fig. 35 Hospitals CAR T-cell therapy market estimates and forecast, 2018 - 2030
Fig. 36 Cancer Treatment Centers CAR T-cell therapy estimates and forecast, 2018 - 2030
Fig. 37 Global CAR T-cell therapy market: Regional movement analysis
Fig. 38 Global CAR T-cell therapy market: Regional outlook and key takeaways
Fig. 39 North America market estimates and forecasts, 2018 - 2030
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030
Fig. 41 Canada market estimates and forecasts, 2018 - 2030
Fig. 42 Europe market estimates and forecasts, 2018 - 2030
Fig. 43 Germany market estimates and forecasts, 2018 - 2030
Fig. 44 UK market estimates and forecasts, 2018 - 2030
Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 46 Japan market estimates and forecasts, 2018 - 2030
Fig. 47 China market estimates and forecasts, 2018 - 2030
Fig. 48 Rest of World market estimates and forecasts, 2018 - 2030
